Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pembrolizumab + pegylated interferon alfa-2b
- Development stage
- Unknown
- Lead developer
- Merck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Intravenous, Subcutaneous
01
Overview
This drug is a **combination of pembrolizumab**, a monoclonal antibody immune checkpoint inhibitor targeting programmed cell death protein 1 (PD-1), and **pegylated interferon alfa-2b**, a pegylated recombinant cytokine that acts as an immunomodulator via the interferon alpha/beta receptor. The combination is being investigated primarily in **advanced/metastatic melanoma**, particularly in PD-1–naïve patients. Clinical trials (Phase Ib/II) support that this combination demonstrates an acceptable toxicity profile and promising evidence of clinical efficacy, with objective response rates around 60% and a 2-year progression-free survival rate of approximately 46%[5][4][7]. The main mechanism underlying the combination is the potential enhancement of anti-tumor immune response through synergistic activation of immune signaling and T cell–mediated immunity.
- Other names
- pembrolizumab plus pegylated interferon alfa-2b
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on pembrolizumab + pegylated interferon alfa-2b.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pembrolizumab + pegylated interferon alfa-2b.